Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myostatin inhibitory-D-peptide-35
- Development stage
- Preclinical
- Modality
- Peptides
- Administration
- Transdermal, Intramuscular
01
Overview
Myostatin inhibitory-D-peptide-35 (MID-35) is a peptide therapeutic agent under investigation for the treatment of sarcopenia, a public health issue affecting older adults characterized by skeletal muscle loss. The drug functions by inhibiting myostatin, a protein known to limit muscle growth. It is being developed for non-invasive intramuscular delivery via iontophoresis, a transdermal drug delivery technology that uses weak electricity to facilitate the passage of macromolecules from the skin surface to skeletal muscle.
02
Targets
Activin AGDF11 (Growth differentiation factor 11)GDF8 (Myostatin)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on Myostatin inhibitory-D-peptide-35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myostatin inhibitory-D-peptide-35.